{"id":134312,"date":"2026-06-29T16:36:29","date_gmt":"2026-06-29T11:06:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=134312"},"modified":"2026-06-29T16:36:31","modified_gmt":"2026-06-29T11:06:31","slug":"piramal-pharma-share-price-target-2026-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/","title":{"rendered":"Piramal Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Piramal Pharma CMP Rs 168. 52W High Rs 221 | Low Rs 132. Mcap Rs 22,320 Cr. 12M Target Rs 220. PE: N\/A.<\/em><\/p>\n<p>The<a href=\"https:\/\/univest.in\/stocks\/pplpharma\/piramal-pharma-ltd-share-price-today\"> Piramal Pharma<\/a> share price target stands at Rs 220 for 2026, implying approximately 31% upside from the current market price of Rs 168. The company is currently in a loss-making phase, and the Piramal Pharma share price target is pegged to its recovery potential, with a market capitalisation of Rs 22,320 Cr. Investors tracking the pharmaceuticals segment are closely watching Piramal Pharma as an emerging opportunity given its 52-week range of Rs 132 to Rs 221. This analysis covers the bull case, bear case, and key catalysts that will define the Piramal Pharma share price target trajectory through 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=piramal-pharma-target\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Piramal_Pharma_Company_Overview_and_Key_Metrics\" title=\"Piramal Pharma Company Overview and Key Metrics\">Piramal Pharma Company Overview and Key Metrics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Why_Is_the_Piramal_Pharma_share_price_target_Set_at_Rs_220_for_2026\" title=\"Why Is the Piramal Pharma share price target Set at Rs 220 for 2026\">Why Is the Piramal Pharma share price target Set at Rs 220 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#FY27_Earnings_Delivery_and_Revenue_Acceleration\" title=\"FY27 Earnings Delivery and Revenue Acceleration\">FY27 Earnings Delivery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Domestic_Formulations_Growth_and_NLEM_Coverage\" title=\"Domestic Formulations Growth and NLEM Coverage\">Domestic Formulations Growth and NLEM Coverage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#USFDA_and_Export_Approvals_Pipeline\" title=\"USFDA and Export Approvals Pipeline\">USFDA and Export Approvals Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Union_Budget_2026_and_Policy_Tailwinds\" title=\"Union Budget 2026 and Policy Tailwinds\">Union Budget 2026 and Policy Tailwinds<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Piramal_Pharma_Share_Price_Target_Short_Term_12_Month_and_Long_Term\" title=\"Piramal Pharma Share Price Target Short Term, 12 Month and Long Term\">Piramal Pharma Share Price Target Short Term, 12 Month and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Short_Term_Piramal_Pharma_Share_Price_Target_3_to_6_Months\" title=\"Short Term Piramal Pharma Share Price Target: 3 to 6 Months\">Short Term Piramal Pharma Share Price Target: 3 to 6 Months<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#12_Month_Piramal_Pharma_Share_Price_Target_2026\" title=\"12 Month Piramal Pharma Share Price Target 2026\">12 Month Piramal Pharma Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Long_Term_Piramal_Pharma_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Piramal Pharma Share Price Target: FY27 to FY28\">Long Term Piramal Pharma Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Bull_Case_and_Bear_Case_for_Piramal_Pharma_Share_Price_Target\" title=\"Bull Case and Bear Case for Piramal Pharma Share Price Target\">Bull Case and Bear Case for Piramal Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Bull_Case_Rs_255\" title=\"Bull Case: Rs 255\">Bull Case: Rs 255<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Bear_Case_Rs_175\" title=\"Bear Case: Rs 175\">Bear Case: Rs 175<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Key_Risks_to_the_Piramal_Pharma_Share_Price_Target_2026\" title=\"Key Risks to the Piramal Pharma Share Price Target 2026\">Key Risks to the Piramal Pharma Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Macro_Headwind_from_Global_Slowdown_and_US_Tariff_Policy\" title=\"Macro Headwind from Global Slowdown and US Tariff Policy\">Macro Headwind from Global Slowdown and US Tariff Policy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Valuation_Risk_and_Earnings_Miss_Scenario\" title=\"Valuation Risk and Earnings Miss Scenario\">Valuation Risk and Earnings Miss Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Competitive_Pressure_in_the_Pharmaceuticals_Segment\" title=\"Competitive Pressure in the Pharmaceuticals Segment\">Competitive Pressure in the Pharmaceuticals Segment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#FII_Selling_and_Broader_Market_Volatility\" title=\"FII Selling and Broader Market Volatility\">FII Selling and Broader Market Volatility<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#How_to_Invest_in_Piramal_Pharma_Stock\" title=\"How to Invest in Piramal Pharma Stock\">How to Invest in Piramal Pharma Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#FAQs_on_Piramal_Pharma_Share_Price_Target_2026\" title=\"FAQs on Piramal Pharma Share Price Target 2026\">FAQs on Piramal Pharma Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#What_is_the_Piramal_Pharma_share_price_target_for_2026\" title=\"What is the Piramal Pharma share price target for 2026?\">What is the Piramal Pharma share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Is_Piramal_Pharma_a_good_stock_to_buy_right_now\" title=\"Is Piramal Pharma a good stock to buy right now?\">Is Piramal Pharma a good stock to buy right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#What_is_Piramal_Pharmas_52-week_high_and_low\" title=\"What is Piramal Pharma&#8217;s 52-week high and low?\">What is Piramal Pharma&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#What_is_the_market_cap_of_Piramal_Pharma\" title=\"What is the market cap of Piramal Pharma?\">What is the market cap of Piramal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#What_are_the_key_risks_to_the_Piramal_Pharma_share_price_target\" title=\"What are the key risks to the Piramal Pharma share price target?\">What are the key risks to the Piramal Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#What_is_the_bull_case_target_for_Piramal_Pharma_in_2026\" title=\"What is the bull case target for Piramal Pharma in 2026?\">What is the bull case target for Piramal Pharma in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#Where_can_I_track_Piramal_Pharma_share_price_live\" title=\"Where can I track Piramal Pharma share price live?\">Where can I track Piramal Pharma share price live?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/piramal-pharma-share-price-target-2026-2\/#How_do_I_invest_in_Piramal_Pharma_stock\" title=\"How do I invest in Piramal Pharma stock?\">How do I invest in Piramal Pharma stock?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Company_Overview_and_Key_Metrics\"><\/span><strong>Piramal Pharma Company Overview and Key Metrics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\" cellspacing=\"0\" cellpadding=\"8\">\n<thead>\n<tr style=\"background: #f2f2f2;\">\n<th>Piramal Pharma<\/th>\n<th>Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>NSE Symbol<\/strong><\/td>\n<td>PPLPHARMA<\/td>\n<\/tr>\n<tr>\n<td><strong>Sector<\/strong><\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td><strong>CMP (Rs)<\/strong><\/td>\n<td>168<\/td>\n<\/tr>\n<tr>\n<td><strong>52W High (Rs)<\/strong><\/td>\n<td>221<\/td>\n<\/tr>\n<tr>\n<td><strong>52W Low (Rs)<\/strong><\/td>\n<td>132<\/td>\n<\/tr>\n<tr>\n<td><strong>Market Cap (Rs Cr)<\/strong><\/td>\n<td>22,320 Cr<\/td>\n<\/tr>\n<tr>\n<td><strong>P\/E Ratio<\/strong><\/td>\n<td>N\/A<\/td>\n<\/tr>\n<tr>\n<td><strong>12M Target (Rs)<\/strong><\/td>\n<td>220<\/td>\n<\/tr>\n<tr>\n<td><strong>Bull Case (Rs)<\/strong><\/td>\n<td>255<\/td>\n<\/tr>\n<tr>\n<td><strong>Bear Case (Rs)<\/strong><\/td>\n<td>175<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Piramal Pharma is a pharmaceuticals company listed on the National Stock Exchange (NSE: PPLPHARMA). With a market capitalisation of Rs 22,320 Cr, the company occupies a defined position in the Indian pharmaceuticals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 221 and a low of Rs 132, before arriving at its current level of Rs 168. Uniresearch analysts project a 12-month Piramal Pharma share price target of Rs 220, with a bull case of Rs 255 and a bear case of Rs 175.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Piramal_Pharma_share_price_target_Set_at_Rs_220_for_2026\"><\/span><strong>Why Is the Piramal Pharma share price target Set at Rs 220 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Delivery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Delivery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>While Piramal Pharma is currently in a loss-making phase, the Piramal Pharma share price target of Rs 220 anticipates a turnaround driven by operational restructuring and revenue recovery. Management focus on cost rationalisation and revenue diversification forms the basis of the recovery narrative embedded in this price target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Formulations_Growth_and_NLEM_Coverage\"><\/span><strong>Domestic Formulations Growth and NLEM Coverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_and_Export_Approvals_Pipeline\"><\/span><strong>USFDA and Export Approvals Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Piramal Pharma, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Piramal Pharma share price target to materialise by year-end.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026_and_Policy_Tailwinds\"><\/span><strong>Union Budget 2026 and Policy Tailwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including pharmaceuticals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Piramal Pharma share price target thesis through improved demand visibility.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Piramal_Pharma_Share_Price_Target_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Piramal Pharma Share Price Target Short Term, 12 Month and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Piramal_Pharma_Share_Price_Target_3_to_6_Months\"><\/span><strong>Short Term Piramal Pharma Share Price Target: 3 to 6 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the near term, the Piramal Pharma share price target for the next 3 to 6 months is pegged at Rs 180, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the pharmaceuticals segment. Technically, the stock needs to hold the Rs 139-145 zone for this short-term target to remain valid.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Piramal_Pharma_Share_Price_Target_2026\"><\/span><strong>12 Month Piramal Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Our 12-month Piramal Pharma share price target is Rs 220. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 220 level represents approximately 31% upside from the current price of Rs 168.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Piramal_Pharma_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Piramal Pharma Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Over a 2 to 3 year horizon, the long-term Piramal Pharma share price target is estimated between Rs 253 and Rs 297, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 168 an attractive accumulation level.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_Piramal_Pharma_Share_Price_Target\"><\/span><strong>Bull Case and Bear Case for Piramal Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_255\"><\/span><strong>Bull Case: Rs 255<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the bull case scenario, Piramal Pharma delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Piramal Pharma share price target could reach Rs 255, implying approximately 52% upside from the current market price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_175\"><\/span><strong>Bear Case: Rs 175<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case of Rs 175 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Piramal Pharma could re-test support levels closer to its 52-week low of Rs 132, representing a downside risk investors should monitor.<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\" cellspacing=\"0\" cellpadding=\"8\">\n<thead>\n<tr style=\"background: #f2f2f2;\">\n<th>Scenario<\/th>\n<th>Target Price (Rs)<\/th>\n<th>Upside\/Downside from CMP<\/th>\n<th>Key Assumption<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Bull Case<\/td>\n<td>255<\/td>\n<td>52%<\/td>\n<td>Strong earnings growth, sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>220<\/td>\n<td>31%<\/td>\n<td>Steady earnings, margin improvement<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>175<\/td>\n<td>4%<\/td>\n<td>Earnings miss, macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Piramal_Pharma_Share_Price_Target_2026\"><\/span><strong>Key Risks to the Piramal Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Macro_Headwind_from_Global_Slowdown_and_US_Tariff_Policy\"><\/span><strong>Macro Headwind from Global Slowdown and US Tariff Policy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Piramal Pharma faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Risk_and_Earnings_Miss_Scenario\"><\/span><strong>Valuation Risk and Earnings Miss Scenario<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If Piramal Pharma reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Pressure_in_the_Pharmaceuticals_Segment\"><\/span><strong>Competitive Pressure in the Pharmaceuticals Segment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The pharmaceuticals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Piramal Pharma&#8217;s revenue trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Selling_and_Broader_Market_Volatility\"><\/span><strong>FII Selling and Broader Market Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Piramal Pharma&#8217;s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Piramal_Pharma_Stock\"><\/span><strong>How to Invest in Piramal Pharma Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Step 1: Research and Fundamental Analysis.<\/strong> Before investing, thoroughly review Piramal Pharma&#8217;s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Piramal Pharma share price target of Rs 220 is achievable.<\/p>\n<p><strong>Step 2: Use Stock Screeners for Live Data.<\/strong><\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Piramal Pharma Live Data on Univest Screener<\/strong><\/a><\/p>\n<p>Monitor key metrics including P\/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Piramal Pharma share price target thesis in real time.<\/p>\n<p><strong>Step 3: Define Your Entry Zone.<\/strong> The current CMP of Rs 168 is within the identified accumulation zone based on the 52-week low of Rs 132 and the Uniresearch target of Rs 220. Consider entering in tranches to average your cost over market fluctuations.<\/p>\n<p><strong>Step 4: Set Stop Loss and Risk Management Levels.<\/strong> Always define a stop-loss level before investing. A prudent stop-loss for Piramal Pharma based on the current technical setup would be in the Rs 148 to Rs 155 range. Never risk more than 2-5% of your portfolio in any single position.<\/p>\n<p><strong>Step 5: Open a Zero-Brokerage Demat Account.<\/strong> To invest in Piramal Pharma at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Piramal Pharma share price target analysis without incurring unnecessary transaction costs.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Piramal Pharma live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Piramal Pharma share price target for 2026 is Rs 220, with a bull case of Rs 255 and a bear case of Rs 175, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 168 with a 52-week range of Rs 132 to Rs 221, Piramal Pharma presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Piramal Pharma share price target outlined here is for educational purposes only.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Piramal_Pharma_Share_Price_Target_2026\"><\/span><strong>FAQs on Piramal Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Piramal_Pharma_share_price_target_for_2026\"><\/span><strong>What is the Piramal Pharma share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Piramal Pharma share price target for 2026, as per Uniresearch estimate, is Rs 220. This implies approximately 31% upside from the current market price of Rs 168.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Piramal_Pharma_a_good_stock_to_buy_right_now\"><\/span><strong>Is Piramal Pharma a good stock to buy right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Whether Piramal Pharma is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Piramal Pharma share price target of Rs 220 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Piramal_Pharmas_52-week_high_and_low\"><\/span><strong>What is Piramal Pharma&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Piramal Pharma&#8217;s 52-week high is Rs 221 and the 52-week low is Rs 132, as of 29 June 2026. The current price of Rs 168 represents a 27% gain from the 52-week low.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Piramal_Pharma\"><\/span><strong>What is the market cap of Piramal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The market capitalisation of Piramal Pharma is approximately Rs 22,320 Cr, as of 29 June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Piramal_Pharma_share_price_target\"><\/span><strong>What are the key risks to the Piramal Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Piramal Pharma share price target of Rs 220 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the pharmaceuticals sector. Any of these factors could delay or reduce the target realisation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_target_for_Piramal_Pharma_in_2026\"><\/span><strong>What is the bull case target for Piramal Pharma in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the bull case scenario, the Piramal Pharma share price target could reach Rs 255, implying approximately 52% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_Piramal_Pharma_share_price_live\"><\/span><strong>Where can I track Piramal Pharma share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can track Piramal Pharma (NSE: PPLPHARMA) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_invest_in_Piramal_Pharma_stock\"><\/span><strong>How do I invest in Piramal Pharma stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> To invest in Piramal Pharma, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker PPLPHARMA on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma share price target 2026 is Rs 220 per Uniresearch estimate. CMP Rs 168, 52W High Rs 221, Low Rs 132. Bull case Rs 255, bear case Rs 175. Full analysis.<\/p>\n","protected":false},"author":35,"featured_media":134533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-134312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782731194:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Piramal Pharma Share Price Target 2026: Bull Case Rs 220, Bear Case"],"rank_math_description":["The Piramal Pharma share price target for 2026 is Rs 220, implying 31% upside from CMP Rs 168. 52W high Rs 221, low Rs 132. Bull case Rs 255. Expert analysis inside."],"rank_math_focus_keyword":["Piramal Pharma share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["134533"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["22082"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Piramal-Pharma-Share-Price-Target-2026-Analyst-Forecast-Bull-and-Bear-Case.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/134312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=134312"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/134312\/revisions"}],"predecessor-version":[{"id":134534,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/134312\/revisions\/134534"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/134533"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=134312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=134312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=134312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}